Sveriges mest populära poddar
The Journal.
NyheterDagliga nyheter

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

19 min•21 maj 2025
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Fler avsnitt av The Journal.

Visa alla avsnitt av The Journal.
Is the High Over for Hemp Drinks?
•17 min
The Adult Women Caught in Epstein’s Web of Abuse
•22 min
How Do You Refund $166 Billion?
•18 min
Israel Wants "Decisive Victory" in Iran. Is It Succeeding?
•20 min
Is ChatGPT Ready for Sex?
•21 min
The New Legal Strategy That Beat Social Media
•21 min
Fertility Inc.: The Embryo Editing Dinner
•26 min
How Jeffrey Epstein Made Millions From His Connections
•25 min
How ICE Went From Deport… to Airport
•21 min
Iran Thinks It’s Winning the War
•19 min

The Journal. med The Wall Street Journal & Spotify Studios finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.